黄色直播

This competitive grant program seeks to support independent medical education activities that will increase knowledge of the new Guideline-based treatment recommendations and how that may shift the emerging treatment landscape in earlier lines of therapy, including muscle invasive bladder cancer (MIBC). Projects considered for grant support will focus on one or more of the following:

• Guideline recommended care in first-line metastatic urothelial carcinoma (mUC) and the holistic management of patients with UC, including combination regimens and optimal sequencing;
• Early identification and management of adverse events associated with UC treatment within the multidisciplinary team; and/or

The role of antibody-drug conjugates (ADCs) and their targeted MOA to potentially address the unmet need in earlier stages of UC.

Individual projects requesting up to $250,000 will be considered although smaller, focused projects with lower budgets will be preferred. Projects covering multiple activities over time may request up to $500,000. Funding will be allocated for 1-2 larger projects with the majority of the total available budget going toward multiple smaller projects (e.g. $50,000 - $80,000.)

The suggested maximum project length is 18 months.

Contact Details

Internal: ird@dal.ca
External: Pfizer Grant Officer, Lori Carpenter (Lori.carpenter@pfizer.com) and the Astellas Grants Director, Riaz Baxamusa (Riaz.baxamusa@astellas.com), with the subject line 鈥�2024 ONC mUC and MIBC鈥�.

Deadlines

Internal: July 5, 2024 at 4:30pm.
External:聽 July 19, 2024 at 11:59pm EST

罢丑别听grants facilitator聽for your faculty can be found on the staff contact page. For additional resources,聽click here for guidance聽on internal deadlines and submission processes.